Skip to search boxSkip to navigationSkip to main content

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

  • Gina Ma
    ,
  • Yi Wang
    ,
  • Tahmeena Ahmed
    ,
  • Ann Leslie Zaslav
    ,
  • Laura Hogan
    ,
  • Cecilia Avila
*Corresponding author for this work
  • iCell Gene Therapeutics LLC
    ,
  • Stony Brook Medicine
    ,
  • Stony Brook University
    ,
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 42-44 (3 pages)

Journal (Volume, Issue Number)

Leukemia Research Reports (Volume 9)

Publication milestones

  • Published - 2018

Publication status

Published - 2018

ISSN

2213-0489

Publication IDs

  • Scopus: 85045192515

Publication metrics

Metrics

Scopus
citations
SciVal
citations
4
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
SciVal
FWCI
0.33
SciVal
Author count
8
SciVal
Paper percentile
62

PlumX, opens in new tab

Captures
21
Citation count
22